Chronobiological food for infants and method for producing same

EP4463011A1Pending Publication Date: 2024-11-20PADITZ EKKEHART
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
EP2023700806
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-01-13
Filing Date
2023-01-12
Publication Date
2024-11-20

AI Technical Summary

Technical Problem

Current infant formulas lack the dynamic chronobiological changes present in breast milk, particularly in melatonin concentration, which are crucial for regulating infants' sleep patterns and day-night rhythms, leading to suboptimal sleep quality and potential disorders associated with melatonin deficiency.

Method used

The use of non-pooled milk from mammals, such as cows, which is collected at specific times to reflect natural melatonin fluctuations, is incorporated into infant formula production, ensuring the formula mimics the natural circadian changes in breast milk, thereby providing melatonin-rich or melatonin-poor formulations tailored to daytime or nighttime feeding.

Benefits of technology

This approach enhances sleep quality in infants by aligning their melatonin intake with natural rhythms, potentially reducing sleep disorders and supporting the development of a healthy day-night rhythm, while also addressing melatonin deficiency-related issues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1.1
    Figure 1.1
Patent Text Reader

Abstract

A method for producing food for infants, in particular infant formula, is described. The method is distinguished in that non-pooled milk for a mammal is provided as starting material for producing the infant food. Further addressed are an infant food as such, the use of non-pooled milk, in particular as chrononutrition, as well as melatonin and melatonin-containing infant food for use in a method for preventing and / or treating sleep disorders in infants and / or in a method for preventing conditions and sequelae thereof that may result from melatonin deficiency in the first months of life.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CHRONOBIOLOGICAL INFANT FOOD AND METHOD FOR ITS PRODUCTION

[0002] The present invention relates to an infant formula and a method for its production. Furthermore, the invention addresses the use of non-pooled milk for the production of infant formula, as well as the use of melatonin and melatonin-containing infant formula for use in a method for the prevention and treatment of sleep disorders in infants and other disorders that may be associated with melatonin deficiency.

[0003] The object of the present invention is to provide an improved infant formula. A further object is to enable the infant to sleep well and support the development of a day-night rhythm. A further object is to influence conditions and their consequences that may be associated with melatonin deficiency in the first months of life.

[0004] When a baby is born, its natural first food is breast milk, which is optimally tailored to the infant's needs. For this reason, the World Health Organization (WHO) recommends that infants be exclusively breastfed for the first six months. Representative studies show that in Germany, for example, the initial breastfeeding rate has increased continuously since the 1990s and has risen to over 80% since the 2003 / 2004 birth years. However, the breastfeeding rates for exclusive breastfeeding for at least four and six months in Germany for the birth years 2012 to 2016 were only 40.0% and 12.5% ​​respectively. Since no complementary foods can be given up to and including the fourth month of life, conversely 60% of all infants are given an industrial alternative to breast milk before complementary foods are introduced.According to a 2014 study examining breastfeeding behavior in Switzerland, 95% of mothers breastfed their children from the beginning. Over 50% of children were exclusively breastfed for at least 12 weeks of their lives, with approximately 60% remaining fully breastfed up to and including the fourth month of life. The remaining 40% rely partially or entirely on an industrial alternative to breast milk.

[0005] For all those babies who - for whatever reason - cannot be breastfed, there is an alternative in the form of industrially produced ready-made baby food, which is divided into infant formula, follow-on formula and supplementary food. Infant formula is specifically designed for feeding in the first six months of life and is the focus of this invention. With a history dating back to the middle of the 19th century, ready-made baby food has changed massively over time and infant formula in particular has become ever more similar to the original, breast milk. Nevertheless, breast milk is still a big step ahead of today's infant formula. For example, breast milk not only nourishes babies but also protects them from infections.Responsible for this are the antibodies and complex sugar molecules contained in the milk, which help to colonize the intestines with good bacteria. Although commercially available infant formulas contain many nutrients, they do not offer nearly the same level of immune protection. The composition of breast milk also changes constantly, not just over the course of weeks and months, but even within minutes: at the beginning of a feeding, breast milk is more watery to quench the infant's thirst; towards the end, the fat content increases significantly to satisfy the infant. In addition to the changes in composition over the course of the first few months of life and during a breastfeeding session, the composition of breast milk also changes throughout the day.All in all, it can be said that breastfeeding is far superior to feeding industrial infant formula, which shows no variation within a product and lacks many of the unique characteristics with regard to nutrients, hormones and immune defense.

[0006] The present invention aims, among other things, at producing an improved industrial infant formula that, in particular, better reflects the chronobiological changes in the composition of breast milk over the course of a day. This object is achieved by a method for producing infant formula, in particular infant formula, according to claim 1.

[0007] This is a process for producing infant formula characterized by the fact that the milk provided as starting material for production is non-pooled milk. This milk comes from at least one mammal, with the mammal(s) preferably being even-toed ungulates, in particular cows, sheep, horses, donkeys and / or goats. Due to the rather sensitive stomachs of infants, the use of milk from only one mammalian species - particularly cow's milk - is preferred, in accordance with the recommendations of professional societies. However, a combination of two or even more milks from different mammals is possible. The term "infant" - in line with general expert knowledge - refers to a child in its first year of life, i.e. a baby from 0 to 12 months, whereby the term "child" in turn refers to a human being in the life stage of childhood."Animal children" therefore do not fall under the term "infant". Even if, from a biological point of view, humans are mammals, it is customary in the technical field of the present invention to differentiate between the milk of a mammal and breast milk (human milk). Consequently, a person skilled in the art does not consider breast milk to be the milk of a mammal. When the milk of mammals is referred to in the invention, this only means the milk of animals that suckle their young and not human breast milk. In other words, the method comprises the step of providing non-pooled milk from one or more mammals, preferably from one animal species in each case. Industrial infant formulas are usually a milk powder enriched with, among other things, various fats, trace elements, vitamins as well as sodium, magnesium and calcium.Accordingly, the method may include the step of adding fat(s), trace elements, vitamins, sodium, magnesium, and / or calcium. If the infant formula is to be provided in powder form, the free water is removed from the non-pooled milk, for example by heating and / or under vacuum, to convert it into milk powder. To obtain one kilogram of dry milk powder, between six and seven liters of non-pooled fresh milk are required.

[0008] Typically, powdered infant formula is produced as described below. After the raw milk has been provided and treated, a liquid mixture is produced from this and various powdered additives, such as lactose and protein. A high-shear mixer ensures that the additives dissolve in the milk. By evaporation, most of the water is removed from the milk enriched with additives. The milk is then dried in a spray dryer to form a free-flowing and easily soluble, agglomerated powder. Before the spray-dried powder thus obtained is portioned and filled, it is mixed with other additives, particularly temperature-sensitive additives, such as minerals and vitamins. Basically, pooled milk is milk that is made up of milk units orMilk from at least two milkings, which in particular took place at different times over the course of a day. A milk unit is a specific volume or quantity of milk which in particular comes from a single milking. A milking can be understood as the milking of a single mammal, as well as the milking of all animals or just some of the animals, whereby the milking is characterized by the fact that it takes place within a limited time frame. The cows usually go to the milking parlor twice a day. This means that two milkings take place, i.e. each animal - and thus all of the animals - is milked twice a day, usually once in the morning, e.g. at 7.30 a.m., and once in the evening, e.g. at 6 p.m. The average time interval between the milk unit from the morning milking and the milk unit from the evening milking is therefore 10.30 hours.With 30-40 cows and one worker, one milking process takes approximately 1 hour. Non-pooled milk within the meaning of the invention is therefore the milk from one milk unit that comes from only one milking process and was obtained in particular at a specific time of day, or milk from several milk units, whereby the milk units can come from several milking processes that were, however, obtained in a narrow time window over a 24-hour period (e.g. the narrow time window is at least less than 12 hours, preferably less than 9 hours, more preferably less than 6 hours or even only 3 hours, 2 hours or 1 hour, e.g. from 5 p.m. to 6 p.m.).However, the 24 hours do not have to represent the same day, i.e. milk that is made up of a first milk unit, obtained on day X at a specific time of day and within a narrow time window, and a second milk unit obtained on day X + n (n = natural number) at essentially the same specific time of day and within the essentially identical narrow time window, also qualifies as non-pooled milk. The time windows are preferably chosen so that the composition of the milk does not change significantly during this time with regard to at least one target parameter (e.g. melatonin) that is subject to chronobiological changes over the course of a day. The pooled and non-pooled milk can generally come from one barn or one farmer, but also from several barns or farmers.Essentially, the only relevant factor in distinguishing between pooled and non-pooled milk is the timing of milk collection within a 24-hour cycle. This is due to the chronobiological changes in the composition of the milk, as described below.

[0009] Non-pooled milk within the meaning of the invention is further characterized in that chronobiological changes in the composition of the milk within a period of 24 hours are maintained and are not neutralized by mixing with milk from a milking process at a significantly different time during the day (e.g., a milking process outside the narrow time window). Accordingly, milk from a milking process that is 24 hours apart from the previous milking process is non-pooled milk within the meaning of the invention, since chronobiological changes in the composition of the milk over the course of the day would still be detectable.

[0010] The aim is to use non-pooled milk to produce milk powder for infant formula that does not have an average melatonin concentration, but rather either a high melatonin concentration or a low melatonin concentration. Melatonin is a hormone that is synthesized from serotonin in the human and mammalian organism and has a significant influence on the day-night rhythm of the human body. Melatonin is also a metabolite of tryptophan metabolism, the formation of which is controlled by the circadian rhythm and inhibited by light. It has a biological half-life of 30-45 minutes, is metabolized in the liver, and approximately 95% is excreted in the urine as 6-sulfatoxymelatonin.

[0011] The melatonin concentration in breast milk changes over the course of a day. This is particularly important because infants have a reduced melatonin concentration in their blood from the first days of life until the 2nd, 3rd and 4th month. In babies with psychomotor retardation this is even the case up to the 6th month. Prenatally and in the first 8 weeks of life, no melatonin synthesis occurs in the pineal gland; a maximum melatonin concentration is not measured until the age of 3-7 years. There is evidence that the pineal gland can react effectively and very quickly in the dark by synthesizing and secreting melatonin from the 3rd month of life at the earliest. The melatonin from breast milk therefore ensures the healthy development of the infant and good sleep. Furthermore, melatonin from breast milk controls the infant's day-night rhythm, which the infant only begins to develop in the 2nd to 3rd month of life.Melatonin therefore plays an important role in harmonizing the infant's rhythm with that of the mother. The fact that breastfed infants cry less, sleep more peacefully, and are less often considered colicky babies is, among other things, related to the better chronobiologically adjusted melatonin supply of breastfed infants. Since breast milk and cow's milk (and also the milk of other mammalian species such as goat's milk) are subject to similar day-night fluctuations in melatonin concentration, the exclusive or at least predominant use of cow's milk as the starting material is preferred in one embodiment.

[0012] It has been found that the addition of the melatonin precursor tryptophan to infant formula in infants with sleep disorders can have positive effects on actigraphically measured sleep parameters as well as on parental satisfaction. However, the acrophase of tryptophan precedes the acrophase of melatonin by several hours, so that the administration of tryptophan must be well timed. The acrophase is the time span between midnight and the maximum value of a circadian rhythmically varying parameter. This is often given together with the nadir, the range of the corresponding minimum value. Among other things, this makes it difficult to control the melatonin concentration in the blood by adding tryptophan.Tryptophan, or more precisely L-tryptophan, is already added to commercially produced infant formula, but the concentration is too low to have a positive effect on the infant's sleep and health. This is not surprising given that commercially produced infant formula does not differentiate between day and night. After all, it is not desirable for the infant to sleep all day and thus be unable to develop a day-night rhythm. In addition, the complexity of the relationships between melatonin, insulin (melatonin as an insulin antagonist), long-chain neutral amino acids and other components in breast milk prohibits a linear intervention that would simply consist of adding an ingredient such as melatonin or tryptophan to the formula of non-breastfed infants.For example, long-chain neutral amino acids compete with tryptophan when it comes to crossing the blood-brain barrier. Insulin, in turn, contributes to the transfer of long-chain neutral amino acids into the muscles and thus increases the amount of tryptophan available for melatonin synthesis in the brain. Simply adding tryptophan to infant formula is also not effective because, on the one hand, tryptophan is the only amino acid that is very tightly bound to the carrier protein album in serum, and, on the other hand, the membrane passage of tryptophan to cross the blood-brain barrier is inhibited by long-chain neutral amino acids. The availability of serotonin in the brain as an intermediate in the synthesis of tryptophan to melatonin is therefore dependent on the quotient between tryptophan and long-chain neutral amino acids.It is not the tryptophan concentration, but rather the ratio in question, that influences sleep parameters in infants. In breast milk, the ratio is approximately 1:8. Consequently, in the industrial production of baby food that is intended to be adapted to breast milk, not only the tryptophan, serotonin, and melatonin content should be considered, but also the concentration of long-chain neutral amino acids (LNAAs). The nine LNAAs include, in addition to tryptophan, phenylalanine, tyrosine, histidine, methionine, threonine, leucine, isoleucine, and valine. But even if one were to face this complex challenge, the melatonin intake would still not be sufficient, since, on the one hand, although tryptophan is generally an important substrate in metabolism, only 1 to 3% of the tryptophan metabolism is used for the synthesis of serotonin and melatonin.On the other hand, the bigger problem is that tryptophan cannot be used for melatonin synthesis in the pineal gland until the third month of life, because the sympathetic innervation of the pineal gland is not yet fully developed by then. This hurdle can be overcome by using mammalian milk as the starting product, which is collected in the morning and evening and administered in the morning as a pick-me-up and in the evening as sleep-supporting chrononutrition. Because the inventive method focuses directly on the chronobiological change in the melatonin concentration in cow's milk by using non-pooled milk, the attempt to imitate this complexity is avoided and an infant formula is provided whose other components are naturally tailored to the melatonin concentration.In addition to melatonin, there are other components whose concentrations are subject to circadian fluctuations, including fats, triglycerides, cholesterol, iron, cortisol, and cortisone. These components can also be supplied to non-breastfed infants in a more tailored manner by using non-pooled milk as the starting material.

[0013] At this point it should be noted that the invention can be applied in its entirety to infant formula in general, but is particularly suitable for infant formula in particular. Infant formulas are characterized by the fact that they are the only foods, alongside breast milk, that fully meet the nutritional needs of infants during the first six months and completely cover their requirements until the introduction of complementary foods (with the exception of vitamins D and K, which are nowadays given as standard supplements). In general, infant formulas (usually referred to as "Pre" or "1") are the most similar to breast milk and should represent the first breast milk substitute regardless of the time of introduction."Pre" milks contain lactose as their sole carbohydrate source (apart from possible traces of glucose), while "ler" milks may contain only lactose as well as small amounts of starch or other carbohydrates (usually maltodextrins, rarely sucrose). The whey-casein ratio in both is approximately 60:40. Since breast milk has a very high lactose content and lactose has a prebiotic effect, lactose should be preferred as a carbohydrate source in infant formulas. Infant nutrition . pdf ?v=l .2 ; "Life phases: Nutrition" by Jeannette Pommer Schwaller). The "Ordinance of the Federal Minister for Health, Family and Youth on Infant Formula and Follow-on Formula" of the Austrian Federation (source: https: / / www.ris.bka.gv.at / eli / bgb 1 / 11 / 2008 / 68), which has the short title "Infant Formula and Follow-on Formula" and was published on February 20, 2008, defines infant formula even more specifically based on its ingredients. Infant formula is made from defined protein sources and other ingredients whose suitability for the special nutrition of infants from birth onwards has been proven by generally accepted scientific findings. For example, the energy content is between 60 and 70 kcal / 100 mL (for prepared formula), the protein content is between 1.8 and 3 g / 100 kcal (for infant formula based on mammalian milk, in particular cow's milk), the max.Taurine content is 12 mg / 100 kcal, choline content is between 7 and 50 mg / 100 kcal, lipid content is between 4.4 and 6.0 g / 100 kcal, and carbohydrate content is between 9 and 14 g / 100 kcal. Only lactose, maltose, sucrose, glucose, maltodextrins, (dried) glucose syrup, and cooked or gelatinized starch may be used. Further limit values ​​can be found in the Federal Law Gazette "Infant Formula and Follow-On Formula" and its annexes, which can be included in this application if necessary. For the sake of clarity, no limit values ​​for ingredients for follow-on milk are given here, as these can also be found in the aforementioned Federal Law Gazette and included in this application.

[0014] In one embodiment of the method, which can be combined with any of the above-mentioned and yet-to-be-mentioned embodiments, provided they do not conflict, at least 50% by volume of the milk used as starting material is non-pooled milk. In other embodiments, at least 65, 70, 75, 80, 85, 90, 95, 98, or 99% by volume of the milk provided as starting material is non-pooled milk.

[0015] In general, the higher the proportion of non-pooled milk in the "starting material milk," the more the melatonin concentration and the concentration of other chronobiologically changing substances in the produced industrial infant formula, and thus also in the ready-to-drink product, reflect the natural chronobiological change. In one embodiment of the process, which can be combined with any of the embodiments mentioned and those to be mentioned, provided they do not conflict, essentially exclusively non-pooled milk is used as the starting material. Pooled milk is then not used as a starting material for the production of industrial infant formula, except perhaps in trace amounts.

[0016] If the use of pooled milk as a starting material for the production of industrial infant formula is completely avoided, a maximum representation of the natural chronobiological change takes place.

[0017] In one embodiment of the process, which can be combined with any of the embodiments to be mentioned, provided they do not conflict, the milk provided as starting material is obtained by milking between 3 a.m. and 7 a.m.

[0018] In particular, milking takes place between 4 a.m. and 6 a.m., preferably at 5 a.m. ± 15 minutes (i.e. between 4:45 a.m. and 5:15 a.m.).

[0019] The inhibition of melatonin production mentioned above is lifted in the dark during the biological night, so that the melatonin concentration rises over the course of the night, with a maximum concentration in humans at around 3 a.m. In cows, for example, the melatonin concentration changes over the course of a day in a similar way to humans: in the early evening the melatonin concentration in their blood begins to rise - and with it a slight delay in their milk too - and by early morning the melatonin concentration has returned to the low level of the rest of the day. In cows, the fluctuation throughout the day depends on the time of year and the associated shifts in the times of sunrise and sunset, between around 5-8 pg / mL and around 35 pg / mL, with the maximum in the blood being reached between 8 p.m. and 11 p.m.To obtain milk that is particularly rich in melatonin, milking should take place in the early morning, with each previous milking taking place in the early evening (for example, 8 to 12 hours before, preferably 9 to 10 hours before), so that the low-melatonin milk of the day does not reduce the concentration of the melatonin-rich "night milk".

[0020] The melatonin concentration in cow's milk, for example, results from the interaction of a) melatonin synthesis (= in the pineal gland, in the retina and in the intestine), b) melatonin secretion in the mammary glands and c) melatonin storage in the cysterns of the mammary glands. After sunset, the melatonin concentration in the blood rises and, after a slight delay, also in the milk. After sunrise, this process stops. As already indicated, the melatonin concentration does not only depend on the time of day: in the morning, blue light components predominate in natural light, which have a particularly strong effect on the suppression of the melatonin system. Morning light exposure with corresponding blue light components therefore contributes to the inhibition of the formation and release of melatonin during the day, so that an even stronger melatonin activity can be induced in the evening.The effectiveness of melatonin as a sleep hormone therefore depends not only on its evening synthesis, storage, and secretion, but is also determined by light exposure in the morning. Light exposure in the evening can also contribute to a reduction in natural evening melatonin activity, which can lead to difficulty falling asleep. Consequently, it is advantageous if the mammals whose milk is used as starting material are not kept in a darkened stable during the day, but receive as much natural light as possible from sunrise to sunset. Background lighting in the stable at night should under no circumstances contain a high proportion of blue light.

[0021] In one embodiment of the method, which can be combined with any of the embodiments mentioned and those yet to be mentioned, provided they do not contradict each other, the milk provided as starting material has a melatonin content of 10 pg / mL to 60 pg / mL inclusive. In particular, the milk has a melatonin content of 20 pg / mL to 50 pg / mL inclusive, and preferably of 20 pg / mL to 40 pg / mL inclusive. In other words, the milk provided as starting material preferably has a melatonin concentration of at least 20 pg / mL, in particular of at least 30 pg / mL, and more particularly of at least 40 pg / mL .

[0022] Since breast milk has such a low melatonin concentration during the day that it is below the detection limit or amounts to only a few pg / mL, the concentration doubles by evening and maximum values ​​in mature breast milk at night are in the range of 20-30 pg / mL or even 40-50 pg / mL, non-pooled mammalian milk with at least 10 pg / mL or, better still, with at least 15 or even 20 pg / mL is a good starting material for a night milk. Milk with a concentration of 20± 10 pg / mL or even 40± 10 pg / mL is particularly suitable for the production of infant formula. If one considers the total amount of melatonin produced by a mammal during the day, at least 70%, in particular at least 80%, more particularly at least 90%, or even at least 95% of this daily amount is found in the milk provided as starting material with melatonin concentrations as just described.

[0023] For triggering the chronobiological effects of melatonin, a melatonin concentration in the blood plasma between 0.10 and 1.0 nM is optimal.

[0024] In one embodiment of the process, which can be combined with any of the embodiments mentioned and those to be mentioned, provided they do not conflict, the milk provided as starting material is obtained by milking between 2:30 p.m. and 6:30 p.m. In particular, milking takes place between 3:30 p.m. and 5:30 p.m., preferably at 4:30 p.m. ± 15 minutes.

[0025] Since the melatonin concentration in milk decreases sharply in the morning and only increases again in the evening, milk with a particularly low melatonin concentration can be obtained at the times mentioned above, which can then be used to produce infant formula, which is specifically designed for feeding or nourishing the infant during the day.

[0026] In one embodiment of the process, which can be combined with any of the embodiments mentioned and those to be mentioned, provided they do not conflict, the milk used as starting material has a melatonin content of less than 10 pg / mL, in particular less than 8 pg / mL. The melatonin concentration is more particularly less than 5 pg / mL, preferably in the range from 0 pg / mL to 3 pg / mL.

[0027] As already mentioned, breast milk has such a low melatonin concentration during the day that it is below the detection limit or amounts to only a few pg / mL. If non-pooled milk from a mammal which has a very low melatonin concentration is used as the starting material for infant formula, this infant formula is perfectly suited to be fed during the day. If one considers the total amount of melatonin produced by a mammal over the day, a maximum of 30%, in particular a maximum of 20%, more particularly a maximum of 10%, or only a maximum of 5% of this daily amount is found in the milk provided as the starting material with melatonin concentrations as described.

[0028] In one embodiment of the method, which can be combined with any of the embodiments mentioned and those to be mentioned, provided they do not conflict, the non-pooled milk is obtained by a milking operation carried out between 6 hours and 18 hours after the previous milking operation. In particular, the non-pooled milk is obtained by a milking operation carried out between 9 hours and 15 hours, or preferably even between 11 hours and 13 hours, after the previous milking operation.

[0029] A sufficiently long interval between milkings ensures that the melatonin-rich night milk is not mixed with the melatonin-poor day milk in the milk containers, and that the desired melatonin concentrations are achieved in the milk obtained from each milking. Preferably, only one milking per night takes place, as frequent night milkings can lead to a reduction in the melatonin concentration.

[0030] In one embodiment of the process, which can be combined with any of the embodiments mentioned and those to be mentioned, provided they do not conflict, the milk used as starting material is obtained by a milking process which is carried out shortly before or at sunrise.

[0031] At sunrise, melatonin production is inhibited, so milking at the beginning or at the onset of this inhibition results in milk that is particularly rich in melatonin, especially if the previous milking took place when the inhibition was lifted, i.e., at sunset. To ensure that milk with a lower melatonin content is not produced, milking can also take place shortly before sunrise, although "shortly before" means about an hour, or particularly half an hour, before.

[0032] In one embodiment of the process, which can be combined with any of the embodiments mentioned and those to be mentioned, provided they do not conflict, the milk used as starting material is obtained by a milking process carried out shortly before or at sunset.

[0033] At sunset the inhibition of melatonin production is lifted, so that milking at the end or when this inhibition is lifted results in milk that is particularly low in melatonin, particularly if the previous milking took place when the inhibition set in, i.e. at sunrise. To ensure that milk with an increased melatonin content is not already produced, milking can also take place shortly before sunset, where shortly before means about an hour, in particular half an hour, before. In one embodiment of the method, which can be combined with any of the embodiments mentioned and those to be mentioned, provided they do not contradict each other, the method is a two-part process. In the first part, melatonin-rich milk is obtained as the first starting material by milking at a first time or in a first time window.In the second part, however, melatonin-poor milk is obtained as a second starting material by milking at a second time or in a second time window. The first time or the first time window is between 3 a.m. and 7 a.m., in particular between 4 a.m. and 6 a.m., preferably at 5 a.m. ± 15 min, or at sunrise. The second time or the second time window is between 2:30 p.m. and 6:30 p.m., in particular between 3:30 p.m. and 5:30 p.m., preferably at 4:30 p.m. ± 15 min, or at sunset. The interval between the first and the second part of the process is between 6 hours and 18 hours, in particular between 9 hours and 15 hours, preferably between 11 hours and 13 hours. The first starting material and the second starting material are processed separately to form a first melatonin-rich infant formula and a second melatonin-poor infant formula.

[0034] This process makes it possible to produce a low-melatonin infant formula, for example as chrononutrition to wake up, and a high-melatonin infant formula, for example as evening chrononutrition to support sleep. The process can of course be carried out several times in succession over several days, weeks, months or even years. It is not necessarily necessary to carry out the first part first and then the second part; rather, the second part can also be carried out first on one day and the first part the following day. Ideally, the first part is milked at or before sunrise, which, depending on the time of year, is between 5:30 and 8:30 a.m. The second part is milked at or before sunset, which, depending on the time of year, is between 4:30 and 9:30 p.m.The day length is accordingly between 8 and 16 hours, so the time between the first milking in the morning and the second milking in the evening is also 8 to 16 hours, and between the evening milking and the morning milking is also 8 to 16 hours. These figures apply to Zurich, Switzerland, and may need to be adjusted for other locations according to the respective geographical time zone.

[0035] In one embodiment of the process, which can be combined with any of the embodiments mentioned and those to be mentioned, provided they do not conflict, the L-tryptophan concentration of the starting material, or of the first starting material in the two-part process, is adjusted. Preferably, the adjustment is made such that the infant formula, in the ready-to-drink state, has an L-tryptophan concentration of at least 15 mg / 100 kcal, or even at least 25 mg / 100 kcal, such as 25 to 37 mg / 100 kcal, in particular 30 to 34 mg / 100 kcal, and more particularly 32 mg / 100 kcal. As already mentioned, tryptophan is an important starting material for a wide variety of metabolic processes, of which only 1 to 3% is attributable to melatonin synthesis. The development of the body and brain depends on tryptophan, and children can absorb this essential amino acid and, at least in their metabolism, process it. Until the age of 3,However, by the 3rd month of life, tryptophan cannot yet be utilized for melatonin synthesis in the pineal gland, as the sympathetic innervation of the pineal gland is not yet fully developed. It is therefore important that the infant formula fed in the evening and at night is made from non-pooled milk, thus providing a higher melatonin concentration.

[0036] Healthy cows have a tryptophan concentration of approximately 7.2 to 7.3 pM in their milk. With a molar mass of 204.23 g / mol, this corresponds to an amount of 1.47 to 1.50 mg / L. With an energy content of 66 kcal per 100 mL of ready-to-drink infant formula, for example, or approximately 152 mL per 100 kcal, cow's milk, in comparison, would only contain 0.228 mg of tryptophan per 152 mL, making supplementing L-tryptophan a sensible option as an important substrate in metabolism.

[0037] In one embodiment of the method, which can be combined with any of the embodiments mentioned and those to be mentioned, provided they do not conflict, the ratio of L-tryptophan to long-chain neutral amino acids (LNAA) is adjusted. Preferably, the adjustment is carried out such that the ratio is 0.126 to 0.134, in particular 0.128 to 0.132, and more particularly 0.130.

[0038] Since tryptophan competes with LNAAs for the transporter in the blood-brain barrier, a deliberately selected ratio can ensure that a sufficient amount of tryptophan actually reaches the brain for metabolism. L-tryptophan is always added because, unlike D-tryptophan, it is non-toxic. Furthermore, it binds 100 times better to the carrier albumin.

[0039] In one embodiment of the method, which can be combined with any of the embodiments mentioned and those to be mentioned, provided they do not conflict, the amount of alpha-lact albumin is adjusted. Preferably, the adjustment is made so that alpha-lact albumin makes up 30 to 42%, in particular 33 to 39%, and more particularly 36%, of the whey protein in the infant formula. Alternatively, alpha-lact albumin is added in an amount of a maximum of 8.3 g / L, based on the ready-to-drink product.

[0040] Alpha-lact albumin acts as a carrier for L-tryptophan and thus ensures that it is available for further metabolism.

[0041] In one embodiment of the method, which can be combined with any of the embodiments mentioned and those yet to be mentioned, provided they do not contradict each other, the one mammal or the multiple mammals are exposed to bright light of at least 200 lux during the day when the animals are kept in a stable, in particular for at least 12 hours, in particular for at least 14 hours, further in particular for at least 16 hours. The bright light preferably has a high blue light component and has, for example, a wavelength of 465 nm. Furthermore, the one mammal or the multiple mammals are exposed to darkness at night for at least 8 hours, in particular for at least 10 hours, further in particular for at least 12 hours.

[0042] In order to achieve the desired high melatonin concentration in the infant formula provided to the infant as night milk, even when using non-pooled infant milk from stable farming, the lighting situation in the stable can be optimized by exposing the mammals to bright light, preferably around 4 p.m., in order to significantly suppress the activity of the melatonin system, so that they can react even more strongly to the darkness in the evening / night - with increased melatonin secretion.

[0043] In one embodiment of the process, which can be combined with any of the embodiments mentioned and those to be mentioned, provided they do not conflict, the non-pooled milk is not heated above 60 ° C during the process. Additionally or alternatively, the non-pooled milk is exposed to a maximum pH of 7.4 throughout the process.

[0044] By not heating the non-pooled milk or the intermediate products based on the non-pooled milk to a temperature above 65°C, in particular above 62°C, and more particularly above 60°C, in any process step on the way to infant (initial) formula, the original melatonin content is largely retained and the melatonin is not destroyed. Temperature ranges for heating from 60°C up to and including 65°C, in particular from 60°C up to and including 62°C, are particularly preferred. The particularly critical steps here are the treatment of the raw milk and the removal of water. The same applies for a pH regime of maximum 7. 4 during the individual processing steps, which also ensures that the amount of melatonin remains largely stable and that no destruction of the melatonin from the non-pooled milk can occur due to an excessively high pH value.

[0045] In one embodiment of the method, which can be combined with any of the embodiments mentioned and those yet to be mentioned, provided they do not contradict each other, at least one to all of the substances from the group L-tryptophan, 5-HTP, serotonin, acetyl serotonin, melatonin, long-chain neutral amino acids (LNAA) and alpha-lact albumin originate from the starting material. This means that of the seven substances mentioned, one, two, three, four, five, six or seven of the substances (exclusively) get into the infant formula via the starting material. In particular, one, two, three, four, five, six or seven of the substances mentioned are not added in any other way. In particular, L-tryptophan, serotonin, long-chain neutral amino acids (LNAA) and / or alpha-lact albumin in any combination is not added in any other way.Preferably, the ratio of L-tryptophan to long-chain neutral amino acids (LNAA) does not need to be adjusted at all or only by removing L-tryptophan or long-chain neutral amino acids (LNAA).

[0046] In one embodiment of the process, which can be combined with any of the aforementioned and yet-to-be-mentioned embodiments, provided they do not conflict, any melatonin originates from the starting material. In particular, no melatonin is added in any other way.

[0047] In one embodiment of the method, which can be combined with any of the embodiments mentioned and those yet to be mentioned, provided they do not contradict each other, the melatonin content is adjusted by removing melatonin originating from the starting material, in particular the melatonin content is adjusted in this way such that it is at least 10 pg / mL, in particular at least 20 pg / mL, further in particular at least 30 pg / mL, and at most 60 pg / mL in the ready-to-drink infant formula.

[0048] In one embodiment of the process, which can be combined with any of the embodiments mentioned and those to be mentioned, provided they do not contradict each other, further melatonin is added to the melatonin originating from the starting material. The amount of further melatonin is, however, small in relation to the amount of melatonin originating from the starting material. In this context, small means at most the same amount, in particular half as large, and further in particular a quarter as large. If the concentration of melatonin from the starting material were to amount to 30 pg / mL in the finished ready-to-drink infant formula, the additional 30 pg / mL, which would be necessary to achieve a final concentration of 60 pg / mL, could be added elsewhere in the sense of a small amount. The amount added in this example would be the same as the amount originating from the starting material.

[0049] In one embodiment of the process, which can be combined with any of the embodiments mentioned and those yet to be mentioned, provided they do not contradict each other, at least one to all of the substances from the group fats, triglycerides, cholesterol, iron, cortisol and cortisone originate from the starting material. This means that of the six substances mentioned, one, two, three, four, five or six of the substances get into the infant formula (exclusively) via the starting material. In particular, one, two, three, four, five or six of the substances mentioned are not added in any other way. In particular, cholesterol, cortisol and / or cortisone are not added in any other combination.

[0050] One aspect of the invention relates to an infant formula, in particular an infant formula, according to claim 22.

[0051] One aspect of the invention relates to an infant formula, in particular an infant formula, according to claim 223.

[0052] This infant formula is characterized by a ready-to-drink melatonin content of less than 10 pg / mL. The preferred concentration ranges from 0 pg / mL to 5 pg / mL, or even up to 3 pg / mL. These low concentrations indicate a commercially available infant formula suitable for daytime feeding.

[0053] Alternatively, in commercially available infant formula suitable for evening and nighttime feeding, the melatonin concentration is between 10 pg / mL and 60 pg / mL. It is particularly preferred to range from 20 pg / mL to 40 pg / mL or even to 50 pg / mL. In particular, it is greater than 20 pg / mL or even greater than 30 pg / mL. While the melatonin concentration in mature human breast milk (corresponds to breast milk from the 28th day of life) is below the detection limit during the day, measured in the early afternoon, it can be as high as 99 ± 34 pmol / L in the middle of the night during the first 3-4 days of life, but is usually closer to a maximum of 40-110 pg / mL or, more specifically, 40-15 pg / mL. Thus, an industrial infant formula which, in its prepared form, has a maximum concentration of melatonin which is also found in human breast milk, is particularly suitable for nighttime feeding.In order to be suitable for feeding in the evening and throughout the night, industrial infant formula should have a concentration that corresponds to the average value of human breast milk over the evening and night-time period, i.e. at least approx. 4 pg / mL, better still approx. 10 pg / mL to 50 pg / mL or a maximum of approx. 20 pg / mL to 60 pg / mL.

[0054] Infant formula that is in powder form and must be mixed with water has a correspondingly higher melatonin concentration. For example, 13 g of powdered formula is mixed with 90 mL of water to obtain 100 mL of ready-to-drink formula. The melatonin concentration in the powder is therefore approximately 8 times higher than in the prepared infant formula. This powdered infant formula is characterized by a melatonin content of less than 80 pg / g. The preferred concentration ranges from 0 pg / g to 40 pg / g. These low concentrations indicate an infant formula suitable for daytime feeding. Alternatively, in powdered infant formula suitable for evening and nighttime use, the melatonin concentration is between 80 and 480 pg / g, particularly between 150 and 400 pg / g. It is particularly preferred to be between 150 and 300 pg / g.

[0055] Depending on body weight, an infant drinks an average of 600 to 800 mL per day in the first six months of life (excluding the first few days after birth). However, the range can be as high as 500 to 1350 mL per day. Especially in the first few weeks, infants consume food evenly spread over 24 hours. Only when they are older do they consume a larger portion of their food during the day, with less or no food needed at night. So if 600 mL is drunk over 24 hours, 200 to 300 mL is consumed in the evening and at night. With a melatonin concentration of 40 pg / mL, for example, a total of 8 or 12 ng of melatonin is administered, for example, spread over 2, 3, 4 or even up to 6 individual feedings. Accordingly, the dose of melatonin per meal is 4 ng, 2.7 ng, 2 ng, or even 1.3 ng, or 6 ng, 4 ng, 3 ng, or even 2 ng. Contrary to popular belief, it is by no means necessary to administer a dose of 0.1 to 10 mg or even more to achieve an effect.Rather, a melatonin dose of less than 0.1 mg is sufficient, or even less than 10 pg, or even less than 1 pg, so a dose in this range can be aimed for. The preferred dose per administration of melatonin-rich night milk as infant formula is approximately 0.1 ng to 100 ng, especially between 0.5 ng to 50 ng, and more particularly between 1 ng or 2 ng to 20 ng. This dose should be administered once in the evening and, if necessary, once or even once more during the night.

[0056] In one embodiment of the infant formula, which can be combined with any of the embodiments mentioned and those to be mentioned, provided they do not conflict, the concentration of L-tryptophan in the ready-to-drink state is 25 to 37 mg / 100 kcal, in particular 30 to 34 mg / 100 kcal, further in particular 32 mg / 100 kcal.

[0057] In one embodiment of the infant formula, which can be combined with any of the embodiments mentioned and those to be mentioned, provided they do not conflict, the quotient of L-tryptophan to long-chain neutral amino acids (LNAA) is 0.126 to 0.134, in particular 0.128 to 0.132, further in particular 0.130.

[0058] In one embodiment of the infant formula, which can be combined with any of the embodiments mentioned and those to be mentioned, provided they do not conflict, the amount of alpha-lact albumin is 30 to 42%, in particular 33 to 39%, further in particular 36%, of the total whey protein.

[0059] A further aspect of the invention relates to a use of non-pooled milk according to claim 27. Said use concerns the use of non-pooled milk from one or more mammals, in particular cow's milk, sheep's milk, mare's milk and / or goat's milk, for producing infant (initial) food. In particular, the non-pooled milk is used for producing infant (initial) food as chrononutrition. Preferably for producing morning chrononutrition to wake up and / or for producing evening chrononutrition to support sleep. Chrononutrition is understood to mean food that is adapted to naturally occurring chronobiological rhythms of the concentration of ingredients and to chronobiological rhythms of humans. The intake of this food takes place in accordance with chronobiological rhythms. In the above-mentioned embodiments, this takes place, for example.based on day-night rhythms, so that, for example, food containing melatonin is taken only or preferably in the evening some time before going to sleep. In connection with the present invention, the term is derived in relation to the nutrition of infants from the composition of breast milk, which changes within 24 hours, particularly in the day-night rhythm. This change affects hormones such as melatonin and cortisol, but also immunological parameters. Infant formula rich in melatonin is a particularly effective chrononutrition for infants, since they have a much longer elimination half-life of melatonin compared to adults, and moreover, after oral ingestion they also show a relatively high maximum concentration of melatonin in the plasma. The long half-life is probably due to the immature liver enzymes and also the immature kidney function.Liver enzymes are not fully developed before the 7th or 8th month of life.

[0060] If non-pooled milk is used to produce infant formula instead of pooled milk, this infant formula can reflect the natural variation in melatonin concentration in breast milk. Milk obtained as described in the previously outlined methods for producing infant formula is particularly suitable for this use. That is, milk obtained by milking at a specific time or during a specific time period, with a specific interval between milkings and / or with a specific melatonin concentration.

[0061] In one embodiment of the use, which can be combined with any of the embodiments mentioned and those yet to be mentioned, provided they do not conflict, non-pooled milk is used to produce infant formula, in particular infant formula, which is obtained by milking between 3 a.m. and 7 a.m. In particular, the non-pooled milk used is obtained by milking between 4 a.m. and 6 a.m. and preferably by milking at 5 a.m. ± 15 minutes. The non-pooled milk obtained as described above is used in particular to produce evening sleep-supporting chrononutrition. By using non-pooled milk obtained at night or in the early morning hours, its increased melatonin concentration can be utilized, in particular to obtain infant (initial) formula that has a sleep-supporting effect.

[0062] In one embodiment of the use, which can be combined with any of the embodiments mentioned and those to be mentioned, provided they do not conflict, non-pooled milk is used to produce infant formula, in particular infant formula, which is obtained by milking between 2:30 p.m. and 6:30 p.m. In particular, the non-pooled milk used is obtained by milking between 3:30 p.m. and 5:30 p.m. and preferably by milking at 4:30 p.m. ± 15 min. The non-pooled milk obtained as described above is used in particular to produce morning chrononutrition to wake up.

[0063] By using non-pooled milk obtained during the day, particularly in the afternoon, its low melatonin concentration can be exploited, particularly to produce infant formula that acts as a pick-me-up.

[0064] In one embodiment of use, which can be combined with any of the embodiments mentioned and those to be mentioned, provided they do not conflict, the infant formula is an infant formula for infants in the first six months of life or, preferably, an infant formula for infants in the first four or even three months of life.

[0065] In principle, non-pooled milk can be used to make infant formula for any infant. However, it is particularly preferred for making infant formula for younger infants, i.e., infant formula, since they do not yet have a fully developed day-night rhythm of their own and are unable to produce sufficient amounts of melatonin themselves. If they are not given "daytime formula" and "nighttime formula," but simply a "24-hour formula" based on pooled milk, the infants have trouble finding the right day-night rhythm or only develop it with a delay once they can produce sufficient melatonin themselves.

[0066] Yet another aspect of the invention relates to a medical indication according to claim 31.

[0067] Melatonin is used in a method for the prevention and / or treatment of sleep disorders in infants, particularly in infants up to and including 4 months of age. A reduction in the melatonin level in the blood causes difficulty falling asleep or disruptions to the sleep-wake rhythm. Infants are unable to produce sufficient melatonin themselves in the first few months of life, so it is normally supplied through breast milk. If this is not possible, the administration of melatonin can cure sleep disorders and contribute to the regulation of the sleep-wake rhythm.

[0068] Melatonin can also be used in a method for preventing conditions and their consequences that can arise from melatonin deficiency in the first months of life. The dose is preferably less than 0.1 mg melatonin, even less than 10 pg and even less than 1 μg, in particular between approximately 0.1 ng and 100 ng, in particular between 0.5 ng and 50 ng, and more particularly between 1 ng or 2 ng and 20 ng. It should be given once in the evening and, if necessary, once or even once more at night. Melatonin can also be used in a method for sedating infants for medical examinations such as magnetic resonance imaging (MRI), brainstem audiometry (BERA) and electroencephalography (EEG). These examinations are only carried out when absolutely necessary, as they represent a great burden for the infant.Unlike an adult, it is difficult to explain to an infant what is happening and thus to calm them down. To avoid the need to administer anesthetics or other strong sedatives, melatonin can be used to achieve a sedative effect. Melatonin can also be used in a procedure to assist in the induction of anesthesia or to reduce the after-effects of anesthesia. By taking advantage of the sedative effect, less anesthetic may be needed, or the infant can be transferred into anesthesia more gently, which in turn leads to less stress. Another use of melatonin can be in a procedure to prevent sudden infant death syndrome (SIDS). Studies have shown that SIDS victims have lower concentrations of melatonin in various body fluids compared to infants who died from other causes.Similarly, a case-control study found reduced urinary concentrations of melatonin metabolites in infants with an acute life-threatening event (ALTE). Melatonin can also be used in a procedure for treating infants with perinatal asphyxia or hypoxic encephalopathy.

[0069] The rate at which melatonin is broken down and excreted can vary from individual to individual and may not yet be fully developed, particularly in infancy. Therefore, only relatively low doses within the range described in the present invention should be used. To avoid accumulation due to insufficient excretion, long-term use (> 1 week) should include at least one urine test with determination of the melatonin metabolite melatonin sulfate (synonyms: 6-hydroxymelatonin sulfate, 6-sulfatoxymelatonin) to avoid overdose. Corresponding laboratory tests are available, see, for example: https: / / www.ibl-international.com / en / 6-hydroxymelatonin- sulfate-melatoninsulfate-elisa.In one embodiment of the medical indication, which can be combined with any of the embodiments mentioned and those to be mentioned, provided they do not contradict each other, melatonin is used in a method for treating sleep disorders in infants, in particular in infants up to 4 months of age, wherein the melatonin is given in the evening and, if necessary, additionally at night, preferably with or in the infant formula, in particular infant formula. Furthermore, melatonin can be used in this way in a method for preventing conditions and their consequences that can arise from melatonin deficiency in the first months of life. The dose is preferably less than 0.1 mg melatonin, even less than 10 pg and even less than 1 pg, in particular between approx. 0.1 ng and 100 ng, in particular between 0. 5 ng to 50 ng, especially between 1 ng or 2 ng to 20 ng. It should be taken once in the evening and if necessary.given one more time or even one more time during the night .

[0070] As already described, melatonin essentially controls the sleep-wake rhythm, so that for infants who have not yet sufficiently developed this and therefore have sleep disorders, the evening and / or night-time administration of melatonin can help to avoid and / or treat the sleep disorder. Evening administration is particularly preferred because melatonin is most effective in the evening and at night. This is because the associated melatonin receptors are particularly sensitive to melatonin in the evening and at night and are less active during the day (daytime light-dependent activity). Before administering melatonin as an externally administered medication (i.e. as a single substance), an attempt can or even should be made to administer infant formula based on (predominantly) non-pooled milk as the starting material.In terms of chronobiological and sleep-related effects, melatonin appears to be effective only during the sensitive periods from 8:00 p.m. to 3:00 a.m. – due to the underlying phase response curve (PRC), which in turn is shaped by so-called zeitgeber and clock genes and influenced or modified to a limited extent by other factors. Taking melatonin during the day therefore has little effect.

[0071] Yet another aspect of the invention relates to a medical indication according to claim 33.

[0072] In this case, an infant formula, in particular an infant formula containing melatonin is specifically used in a method for treating sleep disorders in infants, in particular in infants up to and including 4 months of age. Such an infant (initial) formula can further be used in a method for preventing conditions and their consequences that can arise from melatonin deficiency in the first months of life. The dose is preferably less than 0.1 mg melatonin, even less than 10 pg and even less than 1 pg, in particular between approximately 0.1 ng and 100 ng, in particular between 0.5 ng and 50 ng, and furthermore in particular between 1 ng or 2 ng and 20 ng. It should be given once in the evening and if necessary once again or even once again during the night.

[0073] Generally, efforts are made to avoid giving infants any form of medication, so melatonin is optimally administered with infant formula that naturally contains an appropriate melatonin concentration (e.g., 20-50 pg / mL; preferred concentrations can be found, for example, in the description of the method and use) due to the choice of milk used as the starting material for the infant formula. This solves the problem of how to administer melatonin to the infant as a medication, while also preventing intolerance to an excipient or the like.

[0074] Yet another aspect of the invention relates to a medical indication formulated in the Swiss claim formulation according to claim 34.

[0075] This concerns the use of melatonin for the manufacture of a medicament for the treatment of sleep disorders in infants up to and including 4 months of age. Furthermore, melatonin can be used for the manufacture of a medicament for the prevention of conditions and their consequences that can arise from melatonin deficiency in the first months of life. As can be seen from the previous explanations, the "medication" can also be an infant formula (initial formula) that has an appropriate melatonin concentration (e.g., 20-50 pg / mL). The dose is preferably less than 0.1 mg melatonin, even less than 10 pg, and even less than 1 pg, in particular between approximately 0.1 ng and 100 ng, in particular between 0.5 ng and 50 ng, and furthermore in particular between 1 ng or 2 ng and 20 ng. It should be given once in the evening and if necessary once more or even once more at night.

[0076] In one embodiment of melatonin for use in a method for treating or preventing a disease or the like, or a use of melatonin, which may be combined with any of the aforementioned and yet-to-be-mentioned embodiments, provided they do not conflict, the melatonin is provided as an aqueous solution in a liquid, such as water, juice, or milk. Alternatively, the melatonin is provided as a spray containing nanoparticles and / or liposomes.

[0077] Since melatonin is stable in aqueous solution and also in dissolved form in orange juice, milk and similar preparations with an ambient pH value of < 7.4, administration in liquid form at the same time as the administration of infant formula and / or breastfeeding or partial breastfeeding + infant formula does not pose a problem.

[0078] In an embodiment of melatonin for use in a method for treating or preventing a disease or the like or a use of melatonin which can be combined with any of the embodiments mentioned and to be mentioned, provided they do not conflict, the melatonin is not provided as a sustained-release preparation.

[0079] Since melatonin causes pulsatile chronobiological effects , sustained - release preparations should not be used in infancy .

[0080] In one embodiment of melatonin for use in a method for treating or preventing a disease or the like or a use of melatonin or an infant formula containing melatonin, which can be combined with any of the embodiments mentioned and those to be mentioned, provided they do not contradict each other, the amount of melatonin per dose is between 0.1 and 100 ng, in particular between 0.5 ng and 50 ng, more particularly between 1 ng or 2 ng and 20 ng. It should be given, for example, once and if necessary once more or even once more per day or application (e.g. sedation before examination). It is understood that the declared dose is precise and may only be subject to a small fluctuation, such as 2 or 5%.This is not the case with food supplements; the declared doses sometimes vary between + 465 and - 80% compared to the actually detectable concentrations.

[0081] In one embodiment of melatonin for use in a method for treating or preventing a disease or the like, or a use of melatonin that can be combined with any of the embodiments mentioned and those yet to be mentioned, provided they do not contradict each other, the melatonin is administered nasally, in particular by means of a nasal spray. The melatonin is preferably provided in the form of encapsulated nanoparticles. The concentration of melatonin is in particular selected such that the dose is preferably less than 0.1 mg melatonin, even less than 10 pg and even less than 1 pg, in particular between approximately 0.1 ng and 100 ng, in particular between 0.5 ng and 50 ng, and further in particular between 1 ng or 2 ng and 20 ng. The dose is administered, for example, via one or two sprays with the nasal spray. For example, one spray has a volume of 0.05 to 0.15 mL, in particular of 0.08 - 1.0 mL, further in particular of 0.09 mL.

[0082] In one embodiment of melatonin for use in a method for treating or preventing a disease or the like or a use of melatonin which can be combined with any of the embodiments mentioned and those yet to be mentioned, provided they do not contradict each other, the melatonin is administered sublingually, in particular by means of a spray, meltable tablets or chewable capsules. Here too, for sublingual application, melatonin can be provided in the form of encapsulated nanoparticles. The concentration of melatonin is in particular chosen such that the dose is preferably less than 0.1 mg melatonin, even less than 10 pg and even less than 1 pg, in particular between approximately 0.1 ng and 100 ng, in particular between 0.5 ng and 50 ng, and further in particular between 1 ng or 2 ng and 20 ng. The dose is applied, for example, via one or two sprays with the spray. For example, a spray has a volume of 0.05 to 0.15 mL, in particular from 0 . 08 - 1 . 0 mL, further in particular from 0 . 09 mL .

[0083] Yet another aspect of the invention relates to a method of adding melatonin according to claim 44.

[0084] Melatonin is added to an infant formula, in particular to an infant formula produced from pooled milk of one or more mammals or from non-pooled milk of one or more mammals. The non-pooled milk is, for example, an infant formula produced by a process as described in any one of claims 1 to 14.

[0085] In one embodiment of the method for adding melatonin, which can be combined with any of the embodiments mentioned and those to be mentioned, provided they do not conflict, the concentration of melatonin is adjusted such that it is at least 10 pg / mL, in particular 20 pg / mL, more particularly 30 pg / mL, in the ready-to-drink infant formula, and the maximum value is 60 pg / mL. The invention is explained in more detail below using examples.

[0086] Example 1 :

[0087] It is mid-June (summer time) and a Swiss farmer is providing two types of milk for the production of infant formula for a food processing company. The first type of milk is the milk from several cows that he milked on his farm between 4:00 and 5:00 a.m., while the second type of milk is also the milk from several cows that he milked on his farm between 8:00 and 9:00 p.m. Both types of milk are not pooled milk, as the milks are obtained at different specific times of day and are not mixed with each other. This means that the chronobiological change in melatonin concentration within the day is maintained by separating the first and second types of milk. The first type, which is rich in melatonin (e.g. containsOne type of milk, which contains 80% of the melatonin produced by cows in a day, is used to produce a sleep-supporting chrononutrition. The second type of milk, which is low in melatonin (contains, for example, 20% of the melatonin produced by cows in a day), is used to produce a stimulating chrononutrition. Example 2:

[0088] A treatment should be offered for infants who have trouble falling asleep. For this, milk from one or more cows is obtained by milking in the middle of the night, for example, one or two hours before sunrise. The milking immediately before the nighttime milking, in turn, takes place one to two hours after sunset to remove the melatonin-poor milk produced during the day from the udder. Thus, the milk obtained by nighttime milking has a particularly high melatonin content (e.g., 30 pg / mL to 40 pg / mL), and the infant formula made from it can be administered, for example, to treat sleep disorders in infants.

[0089] Example 3:

[0090] Non-pooled milk is provided, obtained by milking goats during a specific time window of approximately one hour, e.g., between 4:00 PM and 5:00 PM. The previous milking took place at sunrise. Said non-pooled goat milk contains a melatonin content of less than 10 pg / mL and is used to produce infant formula, which is intended as chrononutrition to wake up and is therefore fed to the infant during the day. Example 4:

[0091] Melatonin, especially obtained from non-pooled milk (e.g., cow's or sheep's milk) during dark hours (the previous milking took place during daylight hours), is administered to the infant in the evening to prevent sleep disturbances. Administration can be via an infant formula made from the non-pooled infant milk, which contains at least 20 pg / mL melatonin in ready-to-drink form.

[0092] Example 5:

[0093] It is mid-November (winter time) and a Swiss farmer is providing two types of milk for the production of infant formula for a food processing plant. The first type of milk is the milk of several cows that are milked within a 6-hour window. Some are milked on his farm between midnight and 1:00 a.m., others between 2:00 and 3:00 a.m., and still others between 5:00 and 6:00 a.m. The previous time, the cows were milked at sunset, i.e. around 4:45 p.m. The second type of milk is also the milk of several cows that are milked within a 6-hour window. Some are milked on the farm between 12:00 and 1:00 p.m., others between 2:00 and 3:00 p.m., and still others between 5:00 and 6:00 p.m. The previous time, these cows were milked at sunrise, around 1:00 a.m.around 7:30 a.m., milked. Both types of milk are non-pooled milk within the meaning of the invention, since the milk obtained at different time windows is not mixed with each other, so that the chronobiological change in melatonin concentration within the day is maintained by separating the first and second types of milk. The first type, which is rich in melatonin (contains, for example, 85% of the melatonin produced by cows in a single day and / or a concentration of 30 pg / mL), is used to produce a sleep-supporting chrononutrition, the second type of milk, which is low in melatonin (contains, for example, 15% of the melanin produced by cows in a single day and / or a melatonin concentration of 5 pg / mL), is used to produce a stimulating chrononutrition.

[0094] An exemplary embodiment of the present invention is explained in more detail below with reference to a figure. Figure 1 shows an embodiment of the two-part method.

[0095] Figure 1 shows an embodiment of the two-part process. It shows how a first milking of one or more mammals of the same species, such as a cow, sheep, goat, or horse, is milked in a specific time window t1. The time window is, for example, one hour long, starting at 4:30 a.m. and ending at 5:30 a.m., shortly before sunrise. Melatonin-rich "night milk" is collected, which is then

[0096] Infant formula is further processed, suitable for evening and nighttime feedings, and can optionally be sold as a first chrononutrition to promote sleep. After a period Δt of, for example, 13 hours, milking takes place again, specifically in the time window t2, which is, for example, one and a half hours long, starting at 7:30 p.m. and ending at 9:00 p.m., shortly before sunset. During this time, low-melatonin "daytime milk" is collected, which is then further processed into infant formula, suitable for daytime feedings and can optionally be sold as a second chrononutrition to wake up.

Claims

52 Patent claims 1. A method for producing industrial infant formula suitable for humans aged 0 to 12 months, in particular industrial infant starter formula suitable for humans aged 0 to 6 months, characterized in that non-pooled milk from one or more animals of the genus mammal, in particular the genus artiodactyls, further in particular cow's milk, sheep's milk, mare's milk, donkey's milk and / or goat's milk, is provided as starting material, wherein non-pooled milk is understood to mean milk from a single milking or milk from several milkings, wherein the single or the several milkings are carried out at a specific time or in a specific time window with reference to a 24-hour cycle, wherein the specific time window is less than 6 h, in particular less than 3 h, further in particular less than 2 h.

2. The method according to claim 1, wherein, with reference to the total quantity of milk as starting material, the proportion of non-pooled milk is at least 50% by volume, in particular at least 75% by volume, and further in particular at least 90% by volume.

3. Method according to claim 1 or 2, wherein only non-pooled milk is provided as starting material.

4. Method according to any one of claims 1 to 3, wherein the milk provided as starting material is obtained by milking between 3 a.m. and 7 a.m., in particular between 4 a.m. and 6 a.m., preferably at 5 a.m. ± 15 min.

5. Method according to any one of claims 1 to 4, wherein the milk provided as starting material has a melatonin content of 10 pg / mL to 60 pg / mL including inclusive, in particular 20 pg / mL to 50 pg / mL including inclusive, preferably 20 pg / mL to 40 pg / mL including inclusive.

6. Method according to any one of claims 1 to 3, wherein the milk provided as starting material is obtained by milking between 2:30 p.m. and 6:30 p.m., in particular between 3:30 p.m. and 5:30 p.m., preferably at 4:30 p.m. ± 15 min.

7. Method according to one of claims 1 to 3 or claim 6, wherein the milk used as starting material has a melatonin content of less than 10 pg / mL, in particular less than 8 pg / mL, further in particular less than 5 pg / mL, preferably from inclusive of 0 pg / mL to inclusive of 3 pg / mL. 54 8. Method according to any one of claims 1 to 7, wherein the non-pooled milk is obtained by a milking process carried out between 6 hours and 18 hours, in particular between 9 hours and 15 hours, preferably between 11 hours and 13 hours, after the previous milking process.

9. Method according to any one of claims 1 to 5 and 8, wherein the milk used as starting material is obtained by a milking process carried out shortly before or at sunrise.

10. Method according to any one of claims 1 to 3 and 6 to 8, wherein the milk used as starting material is obtained by a milking process carried out shortly before or at sunset.

11. A method according to any one of claims 1 to 3, characterized in that the method is in two parts, wherein: in the first part, melatonin-rich milk is obtained as the first starting material by milking at a first time or in a first time window; in the second part, melatonin-poor milk is obtained as the second starting material by milking at a second time or in a second time window; the first time or the first time window is between 3 11 a.m. and 7 a.m., especially between 4 a.m. 55 at night and 6 a.m., preferably at 5 a.m. ± 15 min, or at sunrise; the second time or time window is between 2:30 p.m. and 6:30 p.m., in particular between 3:30 p.m. and 5:30 p.m., preferably at 4:30 p.m. ± 15 min, or at sunset; and the interval between the first and second part of the process is between 6 hours and 18 hours, in particular between 9 hours and 15 hours, preferably between 11 hours and 13 hours; and wherein the first starting material and the second starting material are processed separately to produce a first melatonin-rich infant formula and a second melatonin-poor infant formula.

12. Method according to any one of claims 1 to 11, wherein the L-tryptophan concentration, in particular of the starting material or the first starting material, is adjusted, preferably such that it is a concentration of 25 to 37 mg / 100kcal, in particular of 30 to 34 mg / 100kcal, and further in particular of 32 mg / 100kcal in the ready-to-drink infant formula.

13. Method according to any one of claims 1 to 12, wherein the ratio of L-tryptophan to long-chain neutral amino acids (LNAA) is adjusted, preferably such that this ratio is adjusted in the ready-to-drink infant formula. 0.126 to 0.134, in particular 0.128 to 0.132, and further in particular 0.

130.

14. Method according to any one of claims 1 to 13, wherein alpha-lact albumin is added, preferably such that it constitutes 30 to 42%, in particular 33 to 39%, and further in particular 36% of the whey protein.

15. A method according to any one of claims 1 to 14, wherein the one mammal or the several mammals, when kept in a barn, are exposed during the day to bright light of at least 200 lux for at least 12 h, in particular for at least 14 h, and further in particular for at least 16 h, which light preferably has a high blue light component and, for example, a wavelength of 465 nm, and wherein the one mammal or the several mammals, when kept in a barn, are exposed at night to darkness for at least 8 h, in particular for at least 10 h, and further in particular for at least 12 h.

16. Method according to any one of claims 1 to 15, wherein the non-pooled milk is not heated above 65°C, in particular not above 62°C, and further in particular not above 60°C, during the process and / or the non-pooled milk is exposed to a pH value of at most 7.4 during the entire process.

17. Method according to any one of claims 1 to 16, wherein at least one to all of the substances from the group L-tryptophan, 5-HTP, serotonin, acetylserotonin, melatonin, long-chain neutral amino acids (LNAA) and alpha-lactalbumin are derived from the starting material and, in particular, at least one to all of the substances from the said group are not added otherwise.

18. Method according to any one of claims 1 to 16, wherein any melatonin originates from the starting material and, in particular, no melatonin is added from any other source.

19. Method according to claim 18, wherein the melatonin content is adjusted by removing melatonin originating from the starting material, in particular the melatonin content is adjusted in this way such that it is at least 10 pg / mL, in particular at least 20 pg / mL, further in particular at least 30 pg / mL, and at most 60 pg / mL in the ready-to-drink infant formula.

20. Method according to any one of claims 1 to 16, wherein further melatonin is added to the melatonin derived from the starting material, wherein the amount of further melatonin is small in relation to the amount of melatonin derived from the starting material, where small means at most equal, in particular half as large, and further in particular one quarter as large. 58 21. Method according to any one of claims 1 to 20, wherein at least one to all of the substances from the group fats, triglycerides, cholesterol, iron, cortisol and cortisone are derived from the starting material and in particular at least one to all of the substances from the group are not added otherwise.

22. Industrial infant formula suitable for people aged 0 to 12 months, in particular industrial infant starter formula suitable for people aged from 0 to 6 months, produced according to a method according to any one of claims 1 to 21.

23. Infant formula, in particular infant starter formula, characterized in that it has a melatonin content of less than 10 pg / mL in its ready-to-drink state, preferably from 0 pg / mL to 5 pg / mL including inclusive, or from 10 pg / mL to 60 pg / mL including inclusive, preferably from 20 pg / mL to 40 pg / mL including inclusive.

24. Infant formula according to claim 22 or 23, wherein the ready-to-drink formula has a concentration of 25 to 37 mg / 100kcal, in particular 30 to 34 mg / 100kcal, and further in particular 32 mg / 100kcal, of L-tryptophan. 59 25. Infant formula according to any one of claims 22 to 24, wherein in the ready-to-drink state it has a ratio of L-tryptophan to long-chain neutral amino acids (LNAA) of 0.126 to 0.134, in particular of 0.128 to 0.132, and further in particular of 0.

130.

26. Infant formula according to any one of claims 22 to 25, wherein alpha-lact albumin constitutes 30 to 42%, in particular 33 to 39%, and further in particular 36% of the whey protein.

27. Use of non-pooled milk from one or more animals of the genus Mammalia, in particular cow's milk, sheep's milk, mare's milk, donkey's milk and / or goat's milk, for the production of industrial infant formula suitable for humans aged 0 to 12 months, in particular for the production of industrial infant formula as chrononutrition, preferably as morning chrononutrition to wake up and / or as evening sleep-supporting chrononutrition.

28. Use according to claim 27, wherein the non-pooled milk is obtained by milking between 3 a.m. and 7 a.m., in particular between 4 a.m. and 6 a.m., and further in particular at 5 a.m. ± 15 min, preferably at sunrise, for the production of infant formula, in particular as evening sleep-supporting chrononutrition. 60 29. Use according to claim 27, wherein the non-pooled milk is obtained by milking between 2:30 p.m. and 6:30 p.m., in particular between 3:30 p.m. and 5:30 p.m., and further in particular at 4:30 p.m. ± 15 min, preferably at sunset, for the production of infant formula, in particular as morning chrononutrition to wake up.

30. Use according to any one of claims 27 to 29, wherein the industrial infant formula is an infant starter formula, in particular for infants in the first six months of life, preferably in the first four or even three months of life.

31. Melatonin for use in a procedure for: Prevention and / or treatment of sleep disorders in infants, especially in infants up to and including 4 months of age; and / or Sedation of infants for medical purposes Examinations such as magnetic resonance imaging (MRI), brainstem auditory evoked response (BAER) and electroencephalography (EEG); and / or Support for the induction of anesthesia and / or reduction of anesthesia-related after-effects; Prevention of sudden infant death syndrome (SIDS); and / or 61 Treatment of infants with perinatal asphyxia; and / or Treatment of infants with hypoxic encephalopathy.

32. Melatonin for use in a method for the prevention and / or treatment of sleep disorders in infants, especially in infants up to and including 4 months of age, wherein the melatonin is administered in the evening, and if necessary additionally at night, preferably with or in the infant formula.

33. Melatonin-containing industrial infant formula for use in a process for: Prevention and / or treatment of sleep disorders in infants, especially in infants up to and including 4 months of age; and / or Sedation of infants for medical purposes Examinations such as magnetic resonance imaging (MRI). (MRI), brainstem auditory evoked response (BAER) and electroencephalography (EEG); and / or Support for the induction of anesthesia and / or reduction of anesthesia-related after-effects; Prevention of sudden infant death syndrome (SIDS); and / or Treatment of infants with perinatal asphyxia; and / or Treatment of infants with hypoxic Encephalopathy.

34. Use of melatonin for the manufacture of a drug for: Prevention and / or treatment of sleep disorders in infants, especially in infants up to and including 4 months of age; and / or Sedation of infants for medical purposes Examinations such as magnetic resonance imaging (MRI), brainstem auditory evoked response (BAER) and electroencephalography (EEG); and / or Support for the induction of anesthesia and / or reduction of anesthesia-related after-effects; Prevention of sudden infant death syndrome (SIDS); and / or Treatment of infants with perinatal asphyxia; and / or Treatment of infants with hypoxic encephalopathy.

35. Melatonin for use in a procedure for the prevention of conditions and their consequences that may arise from melatonin deficiency in the first months of life, especially in infants up to and including 4 months of age. 63 36. Melatonin for use in a procedure for the prevention of conditions and their consequences that may arise from melatonin deficiency in the first months of life, wherein the melatonin is given in the evening, and if necessary additionally at night, preferably with or in the infant formula.

37. Melatonin-containing industrial infant formula for use in a procedure for the prevention of conditions and their consequences that may arise from melatonin deficiency in the first months of life, especially in infants up to and including 4 months of age.

38. Use of melatonin for the manufacture of a drug for the prevention of conditions and their consequences that may arise from melatonin deficiency in the first months of life, especially in infants up to and including 4 months of age.

39. Melatonin according to any one of claims 31, 32, 35, and 36 or a use of melatonin according to claim 34 or 38, wherein the melatonin is provided as an aqueous solution in a liquid, in particular water, juice or milk, or as a spray with nanoparticles and / or with liposomes.

40. Melatonin according to any one of claims 31, 32, 35, and 36 or a use of melatonin according to claim 34 or 64 38, whereby the melatonin is not provided as a sustained-release preparation.

41. Melatonin according to one of claims 31, 32, 35 and 36, an industrial infant formula containing melatonin according to claim 33 or 37, or a use of melatonin according to claim 34 or 38, wherein the amount of melatonin per dose is between 0.1 and 100 ng, in particular between 0.5 ng and 50 ng, and further in particular between 1 ng or 2 ng and 20 ng.

42. Melatonin according to any one of claims 31, 32, 35, 36, 39 and 40, wherein the melatonin is provided nasally, in particular by means of a nasal spray, and further in particular as encapsulated nanoparticles.

43. Melatonin according to any one of claims 31, 32, 35, 36, 39 and 40, wherein the melatonin is provided sublingually, in particular by means of a spray, melt-in-the-mouth tablets or chewable capsules, further in particular as encapsulated nanoparticles.

44. Method comprising: the addition of melatonin to industrial infant formula suitable for persons aged 0 to 12 months, in particular industrial infant starter formula suitable for persons aged from 65 0 to 6 months, produced from pooled milk of one or more mammals; or the addition of melatonin to industrial infant formula suitable for humans aged 0 to 12 months, in particular infant formula suitable for humans aged 0 to 6 months, produced from non-pooled milk of one or more mammals, in particular to an infant formula produced according to a method according to one of claims 1 to 21.

45. Method according to claim 44, wherein the concentration of melatonin is adjusted such that it is at least 10 pg / mL, in particular 20 pg / mL, and further in particular 30 pg / mL in the ready-to-drink infant formula, and the maximum value is 60 pg / mL.